ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $115.16M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 3.55M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +25.63% |
| Volume | 12,060 |
| Open | 32.38 |
| Previous Close | 32.39 |
| Day's Range | 32.40 - 32.75 |
| 52-Week Low | 23.58 |
| 52-Week High | 35.51 |
| Beta | 0.92 |
| Holdings | 120 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by SS&C.
Top 10 Holdings
29.66% of assets| Name | Symbol | Weight |
|---|---|---|
| Prometheus Biosciences, Inc. | RXDX | 5.40% |
| Roivant Sciences Ltd. | ROIV | 4.09% |
| Cerevel Therapeutics Holdings, Inc. | CERE | 2.99% |
| IVERIC bio, Inc. | ISEE | 2.98% |
| Alkermes plc | ALKS | 2.77% |
| Denali Therapeutics Inc. | DNLI | 2.46% |
| Vaxcyte, Inc. | PCVX | 2.32% |
| ACADIA Pharmaceuticals Inc. | ACAD | 2.28% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 2.23% |
| Zai Lab Limited | ZLAB | 2.12% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.78406 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
News
ALPS' Biotech ETF SBIO Week's Top Performer
In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit...
Biotech ETFs' Performance Deserves A Look
Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.
Biotech M&A Could Finally Be Ready to Rebound
One of the long-running catalysts for small- and mid-sized biotechnology companies is the possibility that they'll eventually be acquired by large-cap brethren or blue-chip pharmaceutical firms. While...
Look to SBIO for Biotech Exposure
ETFs offering biotech exposure are rallying on Monday, lifted by a significant M&A announcement in the industry. The ALPS Medical Breakthroughs ETF (SBIO) increased by 1.8% in mid-day trading on Monda...
Gene Deal Adds New Dimension to Biotech ETF SBIO
With technology ETFs taking in $3.2 billion over one month, compared to overall -$4 billion in YTD outflows according to YCharts, investors are looking for the right tech subsector in which to invest.
SBIO Rallied While Major Indexes Declined Last Week
The ALPS Medical Breakthroughs ETF (SBIO) rallied 3.66% last week, outpacing competing biotech ETFs and major U.S. indexes. The biotech sector was propelled last week by long-awaited breakthrough Alzh...
SBIO Outpaced XBI, IBB in Volatile Last Week
Despite last week's volatility, positive sentiment throughout the biotech industry continued to intensify, propelled by favorable legislation and encouraging trial data.
SBIO Was ALPS' Top Performing ETF in August
The ALPS Medical Breakthroughs ETF (SBIO) was ALPS' top-performing ETF in August, propelled by positive earnings and M&A announcements in the portfolio. SBIO increased 8.65% on a total return basis ...
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Gen...
Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Vir...
Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics
Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday...
SBIO Increases on Biotech's Sustained Rebound
A surge in biotech stocks that began in mid-June is lasting longer than skeptics expected, with no signs of slowing down. The ALPS Medical Breakthroughs ETF (SBIO) gained 7.74% in June as positive dru...
Biotech ETFs Are Making a Comeback
Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech ...
SBIO Continues Rally on Breakthrough Drug Data
The ALPS Medical Breakthroughs ETF (SBIO) rallied 11.53% last week on positive trial data and merger and acquisition news that revived the biotech sector. The small- and mid-cap biotech companies amo...
Size Up SBIO as Biotech Catalysts Emerge
Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech ...
Betting on Biotech Bear Market Expiration Date
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...
Positioning for Biotech Bounceback
Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that...
Make Biotech Cash Considerations With SBIO
In financial markets, it's often said that cash is king. That's something to remember when it comes to the biotechnology universe due to the cost-intensive nature of developing new drugs and therapies...
Biotech Stocks, ETFs Starting to Look Healthier
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...
SBIO Is a Good Place to Be for Biotech Innovation
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...
Small-Cap Biotech Opportunity Knocks
Among the most beaten-down assets in the first month of 2022 were biotechnology stocks, with smaller members of that group enduring significant punishment. That's the bad news.
Consolidation Could Come Calling for Biotech in 2022
Expectations are in place for a brisk pace of consolidation in the biotechnology space this year, and that could benefit an assortment of exchange traded funds, such as the ALPS Medical Breakthroughs ...
Biotech M&A Could Finally Perk Up in 2022
Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, ma...
Smaller Biotech Stocks Ready to Perk Up
If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more re...
Memeification of Biotech Stocks Shines Light on This ETF
Biotechnology stocks are healthcare laggards this year, and much of the lagging is concentrated in the small- and mid-cap biotech spaces. However, retail traders are embracing some speculative small-c...